These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23675934)

  • 21. Quantum-Mechanics Methodologies in Drug Discovery: Applications of Docking and Scoring in Lead Optimization.
    Crespo A; Rodriguez-Granillo A; Lim VT
    Curr Top Med Chem; 2017; 17(23):2663-2680. PubMed ID: 28685695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of early in vivo toxicity testing in drug discovery toxicology.
    Fielden MR; Kolaja KL
    Expert Opin Drug Saf; 2008 Mar; 7(2):107-10. PubMed ID: 18324874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of chemically diverse GABA
    Mehta P; Srivastava S; Sharma M; Singh I; Malik R
    Int J Biol Macromol; 2018 Nov; 119():1113-1128. PubMed ID: 30098361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantum mechanics in structure-based drug design.
    Peters MB; Raha K; Merz KM
    Curr Opin Drug Discov Devel; 2006 May; 9(3):370-9. PubMed ID: 16729734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ECVAM and pharmaceuticals.
    Vanparys P
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():221-3. PubMed ID: 12513680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetic registration file for NDA and ANDA procedures.
    Marzo A
    Pharmacol Res; 1997 Dec; 36(6):425-50. PubMed ID: 9446710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory considerations for preclinical development of anticancer drugs.
    DeGeorge JJ; Ahn CH; Andrews PA; Brower ME; Giorgio DW; Goheer MA; Lee-Ham DY; McGuinn WD; Schmidt W; Sun CJ; Tripathi SC
    Cancer Chemother Pharmacol; 1998; 41(3):173-85. PubMed ID: 9443633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-directed combinatorial library design.
    Zhou JZ
    Curr Opin Chem Biol; 2008 Jun; 12(3):379-85. PubMed ID: 18328830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADME and toxicity in early drug discovery.
    Zhong HA
    Curr Top Med Chem; 2013; 13(11):1255-6. PubMed ID: 23675933
    [No Abstract]   [Full Text] [Related]  

  • 34. Overview of drug discovery and development.
    Ator MA; Mallamo JP; Williams M
    Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.
    Ren HC; Sai Y; Chen T
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):121-132. PubMed ID: 30039459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacophore modeling for ADME.
    Guner OF; Bowen JP
    Curr Top Med Chem; 2013; 13(11):1327-42. PubMed ID: 23675939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
    Lather A; Sharma S; Khatkar A
    Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADMET--Fifth Annual SMi Conference.
    Comer JE
    IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.